Know Cancer

forgot password

Phase II Study of Bevacizumab and Doxil in the Treatment of Platinum-Resistant or Refractory Ovarian Cancer

Phase 2
18 Years
Not Enrolling
Ovarian Cancer

Thank you

Trial Information

Phase II Study of Bevacizumab and Doxil in the Treatment of Platinum-Resistant or Refractory Ovarian Cancer


Avastin is a humanized monoclonal antibody (a type of protein that is normally made by the
immune system to help defend the body from infection and cancer). Avastin has been approved
for the treatment of colorectal cancer and lung cancer. Avastin is investigational for the
treatment of ovarian cancer and has not been approved by the United States Food and Drug
Administration (FDA) for this use.

Avastin is thought to work by attaching to a protein called vascular endothelial growth
factor (VEGF) to block its action. VEGF plays a role in the formation of both normal and
abnormal blood vessels. It is present in normal tissues, but is produced in excess by most
solid cancers (tumors). In cancer, VEGF helps blood vessels bring nutrients to tumor cells,
allowing the tumor cells to grow. In laboratory studies with human cancer cells grown in
animals, Avastin has been shown to prevent or slow the growth of different types of cancer
cells by blocking the effects of VEGF.


Doxorubicin is a type of antibiotic that is only used in cancer chemotherapy. It slows or
stops the growth of cancer. Doxorubicin has been approved by the FDA to treat cancers of
the head, neck, cervix, vagina, testes, prostate, uterus and Ewing's tumor.

Inclusion Criteria:

- Patients must be platinum resistant

- Patients will be included in the study based on the following criteria:

- No prior anthracycline use

- PS less or equal 2

- Lab values within certain limits (ANC greater 1000, platelets greater 100,000;
ALT, AST 2 time ULN, creatinine less 2.0)

- No more than 3 prior chemotherapy regimens, only 2 of which can have included
platinum-containing regimens

- Use of effective means of contraception in subjects of child-bearing potential

Exclusion Criteria:

1. Disease-Specific Exclusions:

- Evidence of complete or partial bowel obstruction

- Need for IV hydration or TPN

- Greater 2 prior abdominal surgeries

- History of gastrointestinal perforation

- Gastrointestinal perforation due to any other cause within the last 6 months

2. General Medical Exclusions:

- Inability to comply with study and/or follow-up procedures

- Life expectancy of less than 12 weeks

- Current, recent (within 4 weeks of the first infusion of this study), or planned
participation in an experimental drug study other than a Genentech-sponsored
Avastin cancer study

3. Avastin-Specific Exclusions

- Inadequately controlled hypertension (defined as systolic blood pressure 150
and/or diastolic blood pressure greater 100 mmHg on antihypertensive

- Any prior history of hypertensive crisis or hypertensive encephalopathy

- New York Heart Association (NYHA) Grade II or greater congestive heart failure
(see Appendix E)

- History of myocardial infarction or unstable angina within 6 months prior to
study enrollment

- History of stroke or transient ischemic attack within 6 months prior to study

- Known CNS disease

- Significant vascular disease (e.g., aortic aneurysm, aortic dissection)

- Symptomatic peripheral vascular disease

- Evidence of bleeding diathesis or coagulopathy

- Major surgical procedure, open biopsy, or significant traumatic injury within 28
days prior to study enrollment or anticipation of need for major surgical
procedure during the course of the study

- Core biopsy or other minor surgical procedure, excluding placement of a vascular
access device, within 7 days prior to study enrollment

- History of abdominal fistula, or intra-abdominal abscess within 6 months prior
to study enrollment

- Serious, non-healing wound, ulcer, or bone fracture

- Proteinuria at screening as demonstrated by either:

- Urine protein:creatinine (UPC) ratio 1.0 at screening OR

- Urine dipstick for proteinuria greater or equal 2plus (patients discovered
to have greater or equal 2+ proteinuria on dipstick urinalysis at baseline
should undergo a 24 hour urine collection and must demonstrate less or
equal 1g of protein in 24 hours to be eligible)

- Known hypersensitivity to any component of Avastin

- Pregnant (positive pregnancy test) or lactating. No effective means of
contraception (men and women) in subjects of child-bearing potential

Type of Study:


Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Progression Free Survival (PFS) is the primary outcome measure

Outcome Time Frame:

2 years

Safety Issue:


Principal Investigator

Claire F. Verschraegen, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of New Mexico


United States: Food and Drug Administration

Study ID:




Start Date:

March 2007

Completion Date:

August 2011

Related Keywords:

  • Ovarian Cancer
  • Ovarian Neoplasms



New Mexico Cancer Care Associates Santa Fe, New Mexico  87505-7670
University of New Mexico Albuquerque, New Mexico  87131
New York University Cancer Institute New York, New York  10016